MPR

Atogepant Reduces Menstrual Migraine Days in LUNA Trial

In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.
MPR

Use of GLP-1 Receptor Agonists Increasing Among Children With Obesity

HealthDay News — From 2019 to 2026, there was an increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescribing for children aged 8 to 11 years without diabetes but with obesity, ...
MPR

LSD Derivative DT120 Earns FDA Breakthrough Status for MDD

Phase 3 Emerge trial results show a single 100µg dose of lysergide ODT produced rapid, statistically significant, and durable improvements in depression scores through 12 weeks.
MPR

Therapies Compared for Newly Diagnosed Multiple Sclerosis

B-cell-depleting therapy linked to lower relapse incidence, greater T2 lesion volume reduction compared with oral platform therapies ...
MPR

Pacritinib Receives FDA Fast Track Status for VEXAS Syndrome

FDA grants Fast Track designation to pacritinib for VEXAS syndrome, providing a potential therapeutic option for a severe hemato-inflammatory condition with no current approved treatments.
MPR

Phase 3 METEOROID Data Back Satralizumab Priority Review for MOGAD

The FDA has granted Priority Review to the supplemental Biologics License Application for satralizumab for MOGAD, marking a potential first-in-class targeted treatment for this rare central nervous ...